Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B2 | P37059 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.56 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | THRA | P10827 | 1/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | SMPD1 | P17405 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2308139 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171436 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171425 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171409 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171427 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL29171428 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL31474383 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL11245624 | 0.94 | THRA (0.62) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR | |
| SCHEMBL9285808 | 0.93 | MAPT (0.63) | SMN1; SMN2TSHRKDM4EPOLBMAPT | |
| SCHEMBL8358255 | 0.93 | CYP1A2 (0.55) | HSD17B2NPC1RAB9ASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117550979-B | Vanillic acid derivative and preparation method and application thereof | 广西师范大学 | 2025-03-11 | — | — | CN | disclosed |
| CN-117550979-A | Vanillic acid derivative and preparation method and application thereof | 广西师范大学 | 2024-02-13 | — | — | CN | disclosed |
| US-7745431-B2 | Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5H-2,3-benzodiazepine and uses thereof | VELA ACQUISITION CORPORATION (US) | 2010-06-29 | — | — | US | disclosed |
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | VELA ACQUISITION CORPORATION | 2007-02-08 | — | — | US | disclosed |
| WO-2004073638-A2 | METHOD OF LOWERING BODY TEMPERATURE WITH (S)-2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-09-02 | — | — | WO | disclosed |
| WO-2004050616-A2 | TREATMENT OF IRRITABLE BOWEL SYNDROME AND NONULCER DYSPEPSIA WITH SUBSTITUTED 2,3-BENZODIAZEPINES | VELA PHARMACEUTICALS, INC. (US) | 2004-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032479-A1 | Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines | GABBR2, GABBR1, GABRB3 | HSD17B2 150/4885NPC1 1469/4885RAB9A 2984/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.